827017-71-0

Upstream product

• 827017-69-6 3,3-diethyl-4,5-dihydro-5-(2-hydroxyethyl)-2(3H)-furanone 
• 98-59-9 p-toluenesulfonyl chloride 
• 827017-67-4 5-(2-ethoxy-ethyl)-3,3-diethyl-dihydro-furan-2-one 
• 17133-16-3 ethyl 2,2-diethyl-4-pentenoate 
• 1193397-45-3 6,6-diethyl-7-oxooxepan-4-yl acetate 

Downstream Products

• 1453083-75-4 3,3-diethyl-5-(2-(4-(3-methoxyphenyl)piperazin-1-yl)ethyl) dihydrofuran-2(3H)-one 
• 1453083-76-5 3,3-diethyl-5-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one 
• 1453083-77-6 3,3-diethyl-5-(2-(4-(2-hydroxyphenyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one 
• 1453083-78-7 3,3-diethyl-5-(2-(4-(4-hydroxyphenyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one 
• 1453083-79-8 2-(4-(2-(4,4-diethyl-5-oxotetrahydrofuran-2-yl)ethyl)piperazin-1-yl)benzonitrile 
• 1453083-80-1 4-(4-(2-(4,4-diethyl-5-oxotetrahydrofuran-2-yl)ethyl)piperazin-1-yl)benzonitrile 
• 1453083-81-2 3,3-diethyl-5-(2-(4-(4-nitrophenyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one 
• 1453083-82-3 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)dihydrofuran-2(3H)-one 
• 1453083-83-4 3,3-diethyl-5-(2-(4-(4-fluorobenzyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one 
• 1453083-84-5 5-(2-(4-benzhydrylpiperazin-1-yl)ethyl)-3,3-diethyldihydrofuran-2(3H)-one 
• 1453083-85-6 3,3-diethyl-5-(2-(4-phenylpiperidin-1-yl)ethyl)dihydrofuran-2(3H)-one3,3-diethyl-5-(2-(4-phenylpiperidin-1-yl)ethyl)dihydrofuran-2(3H)-one 
• 1453083-88-9 5-(2-(4-benzoylpiperazin-1-yl)ethyl)-3,3-diethyldihydrofuran-2(3H)-one 

Relevant academic research and scientific papers

Synthesis and evaluation of novel, selective, functionalized γ-butyrolactones as sigma-2 ligands

The sigma-2 (σ2) receptor was discovered nearly 40 years ago and was recently identified as the Transmembrane Protein 97 (TMEM97, also known as MAC30 (Meningioma-associated protein)). Aberrant σ2 activity has been linked to diseases

Design, synthesis, and evaluation of novel, selective γ-butyrolactones sigma-2 ligands

Nearly 40 years after the first disclosure of sigma receptors, the sigma-2 (σ2) receptor was recently identified as the Transmembrane Protein 97 (TMEM97, also known as MAC30 (Meningioma-associated protein). This macromolecule has been associated with a nu

NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma- 2 receptor activity.

5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.

Homologation as a lead modification approach en route to a series of lactone-based muscarinic ligands

Previous work identified the lactone ring as a useful scaffold for the design of muscarinic ligands and reported a lactone-based ligand with an IC 50 of 340 nM. Using homologation as a lead modification approach, a new series of lactone-based c

NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE

Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Synthesis and evaluation of 5-substituted derivatives of 4,5-dihydro-3,3-diethyl-2(3H)-furanone as subtype-selective muscarinic leads

A series of 5-substituted 4,5 dihydro-3,3-diethyl-2(3H)-furanones were prepared and evaluated as ligands for cholinergic receptors. 3,3-Diethyl-5-imidazolylmethyl-2(3H)-furanone (12), showed a three-fold selectivity for the M2 receptor subtype